NASDAQ:NUVA

NuVasive Stock Forecast, Price & News

$68.71
+1.20 (+1.78 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.30
Now: $68.71
$68.90
50-Day Range
$56.17
MA: $63.60
$68.08
52-Week Range
$43.11
Now: $68.71
$69.28
Volume373,398 shs
Average Volume788,643 shs
Market Capitalization$3.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
NuVasive logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Employees2,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$6.74 per share
Book Value$17.58 per share

Profitability

Net Income$65.23 million

Miscellaneous

Market Cap$3.53 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Contrasting Alphatec (NASDAQ:ATEC) and NuVasive (NASDAQ:NUVA)
April 9, 2021 |  americanbankingnews.com
NuVasive (NASDAQ:NUVA) Shares Gap Up to $64.68
April 5, 2021 |  americanbankingnews.com
NuVasive (NASDAQ:NUVA) PT Raised to $80.00
March 31, 2021 |  americanbankingnews.com
NuVasive Inc. Buy
March 27, 2021 |  markets.businessinsider.com
NuVasive (NASDAQ:NUVA) Price Target Raised to $80.00
March 25, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.15 out of 5 stars

Medical Sector

946th out of 2,010 stocks

Surgical & Medical Instruments Industry

93rd out of 168 stocks

Analyst Opinion: 1.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$68.71
+1.20 (+1.78 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive
or view top-rated stocks.

What stocks does MarketBeat like better than NuVasive?

Wall Street analysts have given NuVasive a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NuVasive wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for NuVasive
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Thursday, February, 25th. The medical device company reported $0.59 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.55 by $0.04. The medical device company earned $291.81 million during the quarter, compared to the consensus estimate of $298.51 million. NuVasive had a negative net margin of 0.84% and a positive trailing twelve-month return on equity of 8.00%. During the same quarter in the previous year, the business posted $0.73 EPS.
View NuVasive's earnings history
.

How has NuVasive's stock price been impacted by COVID-19?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NUVA shares have increased by 39.1% and is now trading at $68.71.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NUVA?

16 analysts have issued 1 year price targets for NuVasive's stock. Their forecasts range from $48.00 to $80.00. On average, they anticipate NuVasive's stock price to reach $64.87 in the next twelve months. This suggests that the stock has a possible downside of 5.6%.
View analysts' price targets for NuVasive
or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 48, Pay $2.43M)
  • Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $686.56k)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 51)
  • Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 41)
  • Mr. Johnson Lai, Chief Information Officer
  • Mr. Sean Freeman, Sr. VP of Strategy & Corp. Devel.
  • Mr. Lucas Vitale, Sr. VP & Chief HR Officer (Age 44)
  • Mr. Frank Middeke, Managing Director of DACH
  • Ms. Lisa Pecora, VP & Head of Global Commercial Fin.
  • Mr. Brent J. Boucher, Exec. VP of Global Commercial (Age 54)

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a number of institutional and retail investors. Top institutional investors include Scout Investments Inc. (1.09%), State of Alaska Department of Revenue (0.02%) and Pacer Advisors Inc. (0.01%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive
.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Pacer Advisors Inc..
View insider buying and selling activity for NuVasive
or view top insider-selling stocks.

Which institutional investors are buying NuVasive stock?

NUVA stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc..
View insider buying and selling activity for NuVasive
or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $68.71.

How much money does NuVasive make?

NuVasive has a market capitalization of $3.53 billion and generates $1.17 billion in revenue each year. The medical device company earns $65.23 million in net income (profit) each year or $2.47 on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,700 workers across the globe.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

Where are NuVasive's headquarters?

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.